BioVie Inc. Accretion Expense
BioVie Inc. (BIVI) reported Accretion Expense of $144.00 thousand for the 3-month period ending 2022-09-30, per its 10-Q filed 2022-11-04.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AccretionExpense · last filed 2022-11-04
- BioVie Inc. accretion expense for the quarter ending 2022-09-30 was $144.00K.
- BioVie Inc. accretion expense for fiscal 2022 was $165.00K.
| Period end | Accretion Expense 3 month | Accretion Expense 12 month |
|---|---|---|
| 2022-09-30 | $144.00K 10-Q · filed 2022-11-04 | |
| 2022-06-30 | $165.00K 10-K · filed 2022-09-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |